GYRE vs. IRWD, GMTX, BLTE, COLL, PRTA, MNKD, VRNA, SYRE, MIRM, and PCRX
Should you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Ironwood Pharmaceuticals (IRWD), Gemini Therapeutics (GMTX), Belite Bio (BLTE), Collegium Pharmaceutical (COLL), Prothena (PRTA), MannKind (MNKD), Verona Pharma (VRNA), Spyre Therapeutics (SYRE), Mirum Pharmaceuticals (MIRM), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.
Ironwood Pharmaceuticals received 504 more outperform votes than Gyre Therapeutics when rated by MarketBeat users.
In the previous week, Ironwood Pharmaceuticals had 13 more articles in the media than Gyre Therapeutics. MarketBeat recorded 20 mentions for Ironwood Pharmaceuticals and 7 mentions for Gyre Therapeutics. Ironwood Pharmaceuticals' average media sentiment score of 0.73 beat Gyre Therapeutics' score of 0.24 indicating that Gyre Therapeutics is being referred to more favorably in the news media.
24.0% of Gyre Therapeutics shares are owned by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Ironwood Pharmaceuticals presently has a consensus price target of $18.40, indicating a potential upside of 162.86%. Given Gyre Therapeutics' higher possible upside, research analysts plainly believe Ironwood Pharmaceuticals is more favorable than Gyre Therapeutics.
Gyre Therapeutics has lower revenue, but higher earnings than Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 2.13, indicating that its share price is 113% more volatile than the S&P 500.
Gyre Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -254.41%. Ironwood Pharmaceuticals' return on equity of 0.00% beat Gyre Therapeutics' return on equity.
Summary
Ironwood Pharmaceuticals and Gyre Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Gyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gyre Therapeutics Competitors List
Related Companies and Tools
